FDA concurs with EMA's diabetes drug conclusions

08/1/2013 | Medical Marketing & Media

The FDA said it agrees with the conclusions of the European Medicines Agency's Committee for Medicinal Products for Human Use that rejected a link between a class of diabetes drugs called incretin mimetics and increased risk of pancreatic adverse events including pancreatic cancer. "Our general view is that their conclusions are consistent with our current understanding of the data," the FDA's Center for Drug Evaluation and Research said.

View Full Article in:

Medical Marketing & Media

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD